Chronic kidney disease (CKD) affects more than 700 million people worldwide and is caused by genetic and environmental factors, as well as existing medical conditions. Known genetic risk factors for ...

The REMODEL study clarified which pathways are responsible for semaglutide’s cardiorenal effects in patients with CKD and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) are a ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide positively affected renal fat mass, glomerular hemodynamics, inflammation and cortical fibrosis.